News coverage about Neurotrope (NASDAQ:NTRP) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurotrope earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.3378163759619 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Separately, ValuEngine upgraded Neurotrope from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Neurotrope (NTRP) traded down $0.52 on Monday, reaching $7.18. The company had a trading volume of 75,000 shares, compared to its average volume of 91,102. Neurotrope has a 12-month low of $3.40 and a 12-month high of $29.00. The firm has a market cap of $52.86 and a PE ratio of -2.73.

COPYRIGHT VIOLATION WARNING: This article was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at

Neurotrope Company Profile

Neurotrope, Inc, formerly BlueFlash Communications, Inc, is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with's FREE daily email newsletter.